Paganini et al developed a score for evaluating a child with a malignancy and febrile neutropenia. This can help identify high risk patients who may benefit from more aggressive or a novel therapy. The authors are from the Febrile Neutropenia Study Group, involving investigators in Argentina and Brazil.
Patient selection:
(1) age < 18 years
(2) malignant disease (leukemia, lymphoma, solid organ)
(3) neutropenia following chemotherapy with either an absolute neutrophil count < 500 per µL or an absolute count <= 1,000 per µL with expected nadir to < 500 per µL
(4) >= 1 episode of fever > 38.5°C or >= 2 episodes > 38°C
(5) excluded bone marrow transplantation
Parameters:
(1) advanced stage of underlying malignant disease
(2) associated comorbidity
(3) bacteremia
Parameter |
Finding |
Points |
stage of underlying malignancy |
not-advanced |
0 |
|
advanced |
3 |
associated comorbidity |
none |
0 |
|
present |
2 |
bacteremia |
absent |
0 |
|
present |
1 |
where:
• Advanced stage includes (a) bone marrow involvement, (b) recurrence, (c) development of a second malignancy, (d) therapy with high-dose myelotoxic chemotherapy, or (e) genetic disease.
• Comorbidity included: refractory bleeding, refractory hypoglycemia and hypocalcemia, hypotension, altered mental status, renal insufficiency, hepatic dysfunction, respiratory failure.
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• The higher the score the greater the risk of mortality.
• Low risk patients are discharged 24 hours after hospitalization and followed daily as outpatients. High risk patients remain hospitalized until stable, afebrile and with an absolute neutrophil count > 100 per µL.
Total Score |
Percent Mortality in Derivation Set |
0 to 3 |
0% |
4 |
6% |
5 |
15% |
6 |
40% |
Performance:
• Using a cutoff > 3, the score had a sensitivity of 84% and specificity of 83% for predicting mortality. The negative predictive value was 99.5%.
Specialty: Infectious Diseases, Hematology Oncology